Abstract
SCALOP, a randomized Phase II multicenter trial, compared gemcitabine-chemoradiation (CRT) and capecitabine-CRT following induction chemotherapy in locally advanced pancreatic cancer (LAPC); 74 patients were randomized to a CRT arm. A prospective RTTQA program to ensure protocol compliance and high quality RT delivery involved: (1) RT trial protocol including radiologist outlined example images; (2) Centrally reviewed benchmark case for outlining and planning; (3) Real time, on-trial assessment of RT planning compliance for every patient using a trial specific PAF, to allow all planning data to be compared against protocol standards.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
